In particular, ABT-263 (navitoclax), inhibitor of Bcl-2, Bcl-XL, and Bcl-W, and the less toxic BH3-mimetic targeting only BCL-2, ABT-199 (venetoclax), hold great promise in combinatorial treatment of several cancer types52,53. This evidence concerns the gene BCL2 and cancer.